삼성바이오,아스트라제네카와 3천850억원 바이오의약품 생산계약<br /><br />Samsung Biologics and AstraZeneca have announced a long-term global supply agreement.<br />The deal is valued at nearly 331 million U.S. dollars and will run through 2023.<br />Samsung's biotech unit will provide the large-scale commercial production of drug substances and drug products to support AstraZeneca's biologics therapeutics.<br />The contract price could reach almost 550 million dollars based on demand.<br />It will also allow AstraZeneca to expand its manufacturing capabilities into Asia.<br />Samsung Biologics has racked up orders worth 1.6 billion dollars so far this year.<br /><br />
